Clinical Trial Update: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-finding trial evaluated eribulin mesylate in combination with cetuximab for advanced head and neck cancer and colon cancer; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Head and Neck Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: howard safran | Conditions: Head and Neck Cancer, Colon Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-10